AU641631B2
(en)
*
|
1988-12-23 |
1993-09-30 |
Novo Nordisk A/S |
Human insulin analogues
|
US5716927A
(en)
*
|
1988-12-23 |
1998-02-10 |
Novo Nordisk A/S |
Insulin analogs having a modified B-chain
|
US5126249A
(en)
*
|
1989-05-09 |
1992-06-30 |
Eli Lilly And Company |
Enzymatic removal of a protein amino-terminal sequence
|
DK10191D0
(da)
*
|
1991-01-22 |
1991-01-22 |
Novo Nordisk As |
Hidtil ukendte peptider
|
US5304473A
(en)
*
|
1991-06-11 |
1994-04-19 |
Eli Lilly And Company |
A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
|
IL102240A0
(en)
*
|
1991-06-21 |
1993-01-14 |
Lilly Co Eli |
Insulin analogs
|
GB9316895D0
(en)
|
1993-08-13 |
1993-09-29 |
Guy S And St Thomas Hospitals |
Hepatoselective insulin analogues
|
EP1607086A1
(fr)
*
|
1993-01-29 |
2005-12-21 |
Aradigm Corporation |
Procédé d'utilisation d'insuline monomère en tant que moyen servant à améliorer la réproductibilité de l'insuline inhalée
|
US6131567A
(en)
*
|
1993-01-29 |
2000-10-17 |
Aradigm Corporation |
Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
|
DK72793D0
(da)
*
|
1993-06-21 |
1993-06-21 |
Novo Nordisk As |
Nyt produkt
|
US5461031A
(en)
*
|
1994-06-16 |
1995-10-24 |
Eli Lilly And Company |
Monomeric insulin analog formulations
|
US5504188A
(en)
|
1994-06-16 |
1996-04-02 |
Eli Lilly And Company |
Preparation of stable zinc insulin analog crystals
|
US5474978A
(en)
*
|
1994-06-16 |
1995-12-12 |
Eli Lilly And Company |
Insulin analog formulations
|
US5559094A
(en)
*
|
1994-08-02 |
1996-09-24 |
Eli Lilly And Company |
AspB1 insulin analogs
|
US5547929A
(en)
*
|
1994-09-12 |
1996-08-20 |
Eli Lilly And Company |
Insulin analog formulations
|
US5597893A
(en)
|
1994-10-31 |
1997-01-28 |
Eli Lilly And Company |
Preparation of stable insulin analog crystals
|
US5646242A
(en)
|
1994-11-17 |
1997-07-08 |
Eli Lilly And Company |
Selective acylation of epsilon-amino groups
|
US5693609A
(en)
*
|
1994-11-17 |
1997-12-02 |
Eli Lilly And Company |
Acylated insulin analogs
|
WO1996034882A1
(fr)
*
|
1995-05-05 |
1996-11-07 |
Eli Lilly And Company |
Insuline monocatenaire a bioactivite elevee
|
US5631347A
(en)
*
|
1995-06-07 |
1997-05-20 |
Eli Lilly And Company |
Reducing gelation of a fatty acid-acylated protein
|
US5700904A
(en)
*
|
1995-06-07 |
1997-12-23 |
Eli Lilly And Company |
Preparation of an acylated protein powder
|
HU228094B1
(en)
*
|
1996-06-20 |
2012-10-29 |
Novo Nordisk As |
Insulin preparations containing nacl
|
ES2218622T3
(es)
*
|
1996-07-26 |
2004-11-16 |
Aventis Pharma Deutschland Gmbh |
Derivados de insulina con actividad de union al zinc incrementada.
|
SE520392C2
(sv)
|
1996-09-27 |
2003-07-01 |
Creative Peptides Sweden Ab C |
Specifika peptider för behandling av diabetes mellitus
|
DE19726167B4
(de)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
|
CA2306905A1
(fr)
|
1997-10-24 |
1999-05-06 |
Eli Lilly And Company |
Analogues d'insuline acylee par un acide gras
|
US6531448B1
(en)
|
1997-12-23 |
2003-03-11 |
Eli Lilly And Company |
Insoluble compositions for controlling blood glucose
|
US20010053761A1
(en)
*
|
1998-01-08 |
2001-12-20 |
Dimarchi Richard Dennis |
Method for administering aspb28-human insulin
|
DE19805822B4
(de)
*
|
1998-02-13 |
2009-02-05 |
Solvay Pharmaceuticals Gmbh |
11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
|
CN1125081C
(zh)
*
|
1999-09-08 |
2003-10-22 |
中国科学院上海生物化学研究所 |
重组天然和新型人胰岛素及其制备方法
|
US7202059B2
(en)
|
2001-02-20 |
2007-04-10 |
Sanofi-Aventis Deutschland Gmbh |
Fusion proteins capable of being secreted into a fermentation medium
|
US7638618B2
(en)
|
2001-02-20 |
2009-12-29 |
Sanofi-Aventis Deutschland Gmbh |
Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
AU2003218635A1
(en)
*
|
2002-05-07 |
2003-11-11 |
Novo Nordisk A/S |
Soluble formulations comprising insulin aspart and insulin detemir
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
US7193035B2
(en)
|
2002-10-29 |
2007-03-20 |
Sanofi-Aventis Deutschland Gmbh |
Crystals of insulin analogs and processes for their preparation
|
CN101955527B
(zh)
|
2003-08-05 |
2016-04-20 |
诺沃挪第克公司 |
新型胰岛素衍生物
|
JP4463814B2
(ja)
|
2003-08-05 |
2010-05-19 |
ノボ ノルディスク アクティーゼルスカブ |
新規のインスリン誘導体
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
ATE525083T1
(de)
*
|
2003-11-13 |
2011-10-15 |
Novo Nordisk As |
Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
|
ES2660320T3
(es)
|
2003-11-20 |
2018-03-21 |
Novo Nordisk A/S |
Formulaciones peptídicas que contienen propilenglicol que son óptimas para la producción y para el uso en dispositivos de inyección
|
ES2369895T3
(es)
|
2003-12-03 |
2011-12-07 |
Novo Nordisk A/S |
Insulina monocatenaria.
|
EP1773878B1
(fr)
|
2004-07-19 |
2015-03-04 |
Biocon Limited |
Conjugués insuline-oligomère, préparations et utilisations de ceux-ci
|
JP4933455B2
(ja)
|
2005-02-02 |
2012-05-16 |
ノヴォ ノルディスク アー/エス |
新規のインスリン誘導体
|
US20080171695A1
(en)
|
2005-02-02 |
2008-07-17 |
Novo Nordisk A/S |
Insulin Derivatives
|
JPWO2006093222A1
(ja)
*
|
2005-03-02 |
2008-08-07 |
味の素株式会社 |
インスリンの多量体形成阻害剤
|
JP5366546B2
(ja)
|
2005-08-16 |
2013-12-11 |
ノボ・ノルデイスク・エー/エス |
成熟インスリンポリペプチドの作製方法
|
CA2621344C
(fr)
|
2005-09-14 |
2014-12-16 |
Sanofi-Aventis Deutschland Gmbh |
Clivage de precurseurs d'insulines par un variant de la trypsine
|
ATE519780T1
(de)
|
2005-12-28 |
2011-08-15 |
Novo Nordisk As |
Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
|
ATE557037T1
(de)
|
2006-02-27 |
2012-05-15 |
Novo Nordisk As |
Insulin derivate
|
ES2397659T3
(es)
|
2006-03-15 |
2013-03-08 |
Novo Nordisk A/S |
Mezclas de amilina e insulina
|
ES2548393T3
(es)
|
2006-05-09 |
2015-10-16 |
Novo Nordisk A/S |
Derivado de insulina
|
ES2553154T3
(es)
|
2006-05-09 |
2015-12-04 |
Novo Nordisk A/S |
Derivado de la insulina
|
BRPI0717098B8
(pt)
|
2006-09-22 |
2021-05-25 |
Novo Nordisk As |
análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
|
US9387176B2
(en)
|
2007-04-30 |
2016-07-12 |
Novo Nordisk A/S |
Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
|
WO2008145728A1
(fr)
|
2007-06-01 |
2008-12-04 |
Novo Nordisk A/S |
Préconcentrés spontanément dispersibles comprenant un médicament peptidique dans un excipient solide ou semi-solide
|
WO2008145732A1
(fr)
|
2007-06-01 |
2008-12-04 |
Novo Nordisk A/S |
Compositions pharmaceutiques non aqueuses stables
|
ES2744384T3
(es)
|
2007-06-13 |
2020-02-24 |
Novo Nordisk As |
Formulación farmacéutica que comprende un derivado de insulina
|
NZ586590A
(en)
|
2008-01-09 |
2012-06-29 |
Sanofi Aventis Deutschland |
Insulin analogues or derivatives having an extremely delayed time-action profile
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
PT3228320T
(pt)
|
2008-10-17 |
2020-03-26 |
Sanofi Aventis Deutschland |
Combinação de uma insulina e de um agonista do glp-1
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
JP4959005B2
(ja)
|
2008-10-30 |
2012-06-20 |
ノボ・ノルデイスク・エー/エス |
毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
|
US20120232002A1
(en)
|
2009-07-06 |
2012-09-13 |
Sanofi-Aventis Deutschland Gmbh |
Slow-acting insulin preparations
|
SI2451437T1
(sl)
|
2009-07-06 |
2017-03-31 |
Sanofi-Aventis Deutschlad Gmbh |
Vodni pripravki, ki vsebujejo metionin
|
EP2451472A1
(fr)
|
2009-07-06 |
2012-05-16 |
Sanofi-Aventis Deutschland GmbH |
Préparations d'insuline stables à la chaleur et aux agitations
|
EP2459228B1
(fr)
|
2009-07-31 |
2020-03-04 |
Sanofi-Aventis Deutschland GmbH |
Promédicament comprenant un conjugué insuline-lieur
|
JP5732053B2
(ja)
|
2009-07-31 |
2015-06-10 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
持続型インスリン組成物
|
MY180661A
(en)
|
2009-11-13 |
2020-12-04 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
|
AU2010317994B2
(en)
|
2009-11-13 |
2014-03-06 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist and methionine
|
ES2612468T3
(es)
|
2010-05-10 |
2017-05-17 |
Novo Nordisk A/S |
Procedimiento para la preparación de complejos de insulina-zinc
|
US20140148384A1
(en)
|
2010-08-30 |
2014-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
EP2438930A1
(fr)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Promédicaments comprenant un conjugué de liaison d'exendine
|
PL2632478T3
(pl)
|
2010-10-27 |
2020-03-31 |
Novo Nordisk A/S |
Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
|
BR112013010345A2
(pt)
|
2010-10-27 |
2017-07-25 |
Novo Nordisk As |
tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
|
CN102199206B
(zh)
*
|
2011-03-17 |
2013-03-20 |
甘李药业股份有限公司 |
快速起效且在酸性条件下稳定的胰岛素类似物及其制剂
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
BR112014004726A2
(pt)
|
2011-08-29 |
2017-04-04 |
Sanofi Aventis Deutschland |
combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
BR112014026442A8
(pt)
|
2012-05-01 |
2018-01-16 |
Novo Nordisk As |
combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica.
|
US20130315891A1
(en)
|
2012-05-25 |
2013-11-28 |
Matthew Charles |
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
|
DK2854841T3
(en)
|
2012-06-04 |
2017-05-22 |
Diamedica Inc |
Kallikrein-1-glycosylation isoforms of human tissue
|
US9867869B2
(en)
|
2012-12-12 |
2018-01-16 |
Massachusetts Institute Of Technology |
Insulin derivatives for diabetes treatment
|
NZ707160A
(en)
|
2012-12-19 |
2016-08-26 |
Wockhardt Ltd |
A stable aqueous composition comprising human insulin or an analogue or derivative thereof
|
WO2014102623A1
(fr)
|
2012-12-26 |
2014-07-03 |
Wockhardt Limited |
Composition pharmaceutique
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
AR095986A1
(es)
*
|
2013-04-03 |
2015-11-25 |
Sanofi Sa |
Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
|
EP2991672A1
(fr)
|
2013-04-30 |
2016-03-09 |
Novo Nordisk A/S |
Schéma d'administration d'un nouveau type
|
WO2015044922A1
(fr)
|
2013-09-30 |
2015-04-02 |
Wockhardt Limited |
Composition pharmaceutique
|
JP6641280B2
(ja)
|
2014-01-09 |
2020-02-05 |
サノフイSanofi |
インスリンアナログおよび/またはインスリン誘導体の安定化された医薬製剤
|
AU2015205621A1
(en)
|
2014-01-09 |
2016-07-14 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
WO2015191705A1
(fr)
*
|
2014-06-10 |
2015-12-17 |
California Institute Of Technology |
Insulines non canoniques et leurs utilisations
|
WO2016001862A1
(fr)
|
2014-07-04 |
2016-01-07 |
Wockhardt Limited |
Formulations à libération prolongée d'insulines
|
EP3229828B1
(fr)
|
2014-12-12 |
2023-04-05 |
Sanofi-Aventis Deutschland GmbH |
Formulation à rapport fixe d'insuline glargine/lixisenatide
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
GB201607918D0
(en)
|
2016-05-06 |
2016-06-22 |
Arecor Ltd |
Novel formulations
|
TWI774694B
(zh)
*
|
2016-09-23 |
2022-08-21 |
南韓商韓美藥品股份有限公司 |
具有降低對胰島素受體之親和力之胰島素類似物及其用途
|
US20190290737A1
(en)
|
2016-09-29 |
2019-09-26 |
Arecor Limited |
Novel formulations
|
CN110446501A
(zh)
|
2017-03-09 |
2019-11-12 |
代阿麦迪卡股份有限公司 |
组织激肽释放酶1的剂型
|
GB201707189D0
(en)
|
2017-05-05 |
2017-06-21 |
Arecor Ltd |
Novel formulations
|
GB201707187D0
(en)
|
2017-05-05 |
2017-06-21 |
Arecor Ltd |
Novel formulations
|
GB201707188D0
(en)
|
2017-05-05 |
2017-06-21 |
Arecor Ltd |
Novel formulations
|
WO2019193351A1
(fr)
|
2018-04-04 |
2019-10-10 |
Arecor Limited |
Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
|
CA3094304A1
(fr)
|
2018-04-04 |
2019-10-10 |
Arecor Limited |
Systeme de pompe a perfusion medicale pour l'administration d'un compose d'insuline
|
US20210038506A1
(en)
|
2018-04-04 |
2021-02-11 |
Arecor Limited |
Medical infusion pump system for the delivery of an insulin compound
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
KR20200082618A
(ko)
|
2018-12-31 |
2020-07-08 |
주식회사 폴루스 |
인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
|
WO2021136296A1
(fr)
|
2019-12-30 |
2021-07-08 |
甘李药业股份有限公司 |
Dérivé d'insuline
|
MX2022008139A
(es)
|
2019-12-30 |
2022-10-03 |
Gan & Lee Pharmaceuticals Co Ltd |
Compuestos de glp-1 de acción prolongada.
|
GB202004814D0
(en)
|
2020-04-01 |
2020-05-13 |
Arecor Ltd |
Novel formulations
|